The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; BioAscent; Casdin Capital; Circulogene Theranostics; Clovis Oncology; Curio Science; Curio Science; Eisai; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Medscape; Merck; Novartis; OncLive; Pfizer; Roche; Targeted Oncology; Tesaro; Vaniam Group; Watermark Research Partners; Zentalis
Research Funding - ArQule; AstraZeneca; Bayer; Celgene (I); Clovis Oncology; Cotinga Pharmaceuticals; GOG Foundation (Inst); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Novartis; Roche/Genentech; Tesaro
 
Robert L. Coleman
Employment - US Oncology
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Bryan M. Fellman
No Relationships to Disclose
 
Ying Yuan
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene/Juno; MicuRx Pharmaceuticals; SERVIER; Starpax Medical; Vertex
 
Anil K. Sood
Employment - Amgen (I)
Stock and Other Ownership Interests - Bio-Path Holdings, Inc
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - KIYATEC; Merck; Merck
Research Funding - MTrap
Patents, Royalties, Other Intellectual Property - EGFL6 antibody royalty payment; SiRNA delivery (patents on DOPC, rHDL)
(OPTIONAL) Uncompensated Relationships - Elsevier
 
Pamela T. Soliman
Consulting or Advisory Role - Amgen; Tesaro
Research Funding - Incyte (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Intuitive Surgical
 
Alexi A. Wright
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - NCCN/AstraZeneca (Inst)
 
Neil S. Horowitz
Patents, Royalties, Other Intellectual Property - Up to Date author
 
Susana M. Campos
Honoraria - AstraZeneca; Eisai
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer; Merck; Pfizer/EMD Serono; Repare Therapeutics; Tesaro; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); tesaro (Inst)
 
Charles F. Levenback
No Relationships to Disclose
 
David Marc Gershenson
Stock and Other Ownership Interests - Biogin; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Genentech
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Royalties from Elsevier as book editor; Royalties from UpToDate for authorship
 
Karen H. Lu
No Relationships to Disclose
 
Virginia Bayer
No Relationships to Disclose
 
Sobiya Tukdi
No Relationships to Disclose
 
Alexis Rabbit
No Relationships to Disclose
 
Lone Ottesen
Employment - AstraZeneca
 
Robert Godin
Employment - AstraZeneca
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena; ImmunoMET; SignalChem; Tarveda Therapeutics
Honoraria - AstraZeneca; ImmunoMET; Lilly; Nuevolution; PDX Pharmacy; Symphogen; Tarveda Therapeutics; Tesaro
Consulting or Advisory Role - AstraZeneca; ImmunoMET; Ionis Pharmaceuticals; Lilly; PDX Pharmacy; SignalChem; Symphogen; Takeda/Millennium; Tarveda Therapeutics; Turbine; Zentalis
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; ImmunoMET; Ions Pharmaceuticals; Karus Therapeutics; NanoString Technologies; Pfizer; Prospect Creek Foundation; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - DSP technology patent with Nanostring; HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Chrysalis Biomedical Advisors; ImmunoMET; Michigan Primary Care Consortium; Pfizer; Symphogen
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Mersana; Regeneron; Tesaro
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Regeneron (Inst); Surface Oncology (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
(OPTIONAL) Uncompensated Relationships - Merck